DEB-TACE: Current standards in drug-eluting therapy for liver malignancies

Discover DEB-TACE for liver tumors in our webinar by CIRSE. Learn more on WebinarCafe.

Healthcare Webinar Benefits

Drug-eluting bead transarterial chemoembolization (DEB-TACE) is a relatively new treatment method that uses drug-eluting microbeads to target tumours. It is essential for interventional radiologists to learn the indications, patient selection, procedural techniques, and the associated pros and cons of DEB-TACE treatment. Despite its well-known and proven clinical indication and efficacy, significant debate still persists regarding the most effective use of DEB-TACE, including its comparative efficacy to other techniques (cTACE, bland embolization), optimal embolic particle sizes, tumour staging considerations, potential complications, and overall therapeutic advantages. This webinar will provide participants with a thorough understanding of how to safely and effectively perform DEB-TACE for treating HCC and mCRC, along with insights into its evolving role in the future. During the case discussions, attendees will learn tips and tricks so that they can avoid potential complications and improve the treatment’s clinical value. Attendees will also have the opportunity to ask questions and engage in dynamic, interactive discussions based on real-world clinical experiences.

Learning objectives

1. To learn how to perform safe and effective DEB-TACE by real case examples.

2. To understand patient selection on DEB-TACE for HCC and colorectal metastases.

3. To understand the role of DEB-TACE in the current landscape of liver-directed locoregional therapies.

Programme

Introduction by the moderators

Roberto Iezzi (Rome/IT) and Thomas Kröncke (Augsburg/DE)

Role of DEB-TACE in HCC

Tobias Jakobs (Munich/DE)

Role of DEB-TACE in mCRC

Geert Maleux (Leuven/BE)

Future of DEB-TACE

Thomas Helmsberger (Munich/DE)

Discussion and Q&A

Take-home points by the moderators

Roberto Iezzi (Rome/IT) and Thomas Kröncke (Augsburg/DE)

CME Accreditation

The CIRSE Webinar “DEB-TACE: Current standards in drug-eluting therapy for liver malignancies”, Vienna (ONLINE), Austria, 30/04/2025-30/04/2025 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1.5 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

The accreditation is valid for the live event, as well as the on-demand content for a period of 6 months after the live webinar. Click here to learn more.

Join free of charge!

Access to this webinar is available free of charge to all interested parties. All you need is your CIRSE login details. Don’t have a CIRSE account yet? Not to worry! It only takes two minutes to set up a new account which will enable you to register.